Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE:002317)
China · Delayed Price · Currency is CNY 24.22
-0.42 (-1.70%)
Sep 18, 2026, 3:04 PM CST
SHE:002317 Revenue
Guangdong Zhongsheng Pharmaceutical had revenue of 376.18M CNY in the quarter ending June 30, 2026, a decrease of -43.47%. This brings the company's revenue in the last twelve months to 2.22B, down -7.46% year-over-year. In the year 2025, Guangdong Zhongsheng Pharmaceutical had annual revenue of 2.52B with 2.24% growth.
Revenue (ttm)
2.22B
Revenue Growth
-7.46%
P/S Ratio
9.26
Revenue / Employee
1.27M
Employees
1,757
Market Cap
20.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.52B | 55.32M | 2.24% |
| Dec 31, 2024 | 2.47B | -143.13M | -5.48% |
| Dec 31, 2023 | 2.61B | -65.60M | -2.45% |
| Jan 1, 2023 | 2.68B | 247.06M | 10.17% |
| Jan 1, 2022 | 2.43B | 533.27M | 28.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harbin Pharmaceutical Group | 16.14B |
| Livzon Pharmaceutical Group | 10.75B |
| Tasly Pharmaceutical Group | 8.15B |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.12B |
| Kangmei Pharmaceutical | 4.97B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 4.72B |
| Betta Pharmaceuticals | 3.85B |
| Shanghai Haoyuan Chemexpress | 3.21B |